Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21).
2026 · 1st Quarter (Jan 1 - Mar 31)
BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.)
Filed by TIBER CREEK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2026
- Income
- $70,000.00
- Expenses
- Not reported
- Registrant
- TIBER CREEK GROUP
- Filing UUID
- 14520940-37a1-4851-9e8b-48e1d379b0e7
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to drug pricing and reimbursement for prescription drugs related to the Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to Centers for Medicare and Medicaid Services (CMS).
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.